PMVP Stock Forecast: PMV Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$1.31
+7.38% on the day

The median 12-month analyst price target for PMV Pharmaceuticals, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 59 of 100 as at 18 Nov 2026 — in the upper half.

Market cap
$92.2M
Ticker Nerd rank
59/ 100
Median analyst target
$4.00
Analysts covering
5
Revenue$0.0
Operating income−$18.9M
Net income−$18.1M
Free cash flow−$14.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+8.3%
1M
+4.4%
YTD
+4.8%
1Y
−3.7%
From 52W high
−27.2%
From 52W low
+28.4%
$1.02
$1.80
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores PMV Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
59/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
86
Volatility
84
Growth
79
Momentum
68
Issuance
41
Revisions
33
Quality
32
Value
23

Accruals (86): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (23): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PMVP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PMVP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Jan 26Apr 26Jul 26Oct 26PMVPHigh $5.00Median $4.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5
Buy
0
Hold
0
Sell
$3.00
Low
$4.00
Median
$5.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 Sept 2026HC Wainwright & Co.ReiteratesBuy$5.00
8 July 2026Ladenburg ThalmannAssumesBuy$3.00
13 May 2026OppenheimerMaintainsOutperform—
20 Mar 2025HC Wainwright & Co.ReiteratesBuy—
20 Aug 2024HC Wainwright & Co.ReiteratesBuy—
30 May 2024HC Wainwright & Co.ReiteratesBuy—
14 May 2024HC Wainwright & Co.ReiteratesBuy—
13 May 2024Craig-HallumInitiatesBuy—
12 Apr 2024JefferiesInitiatesBuy—
7 Mar 2024HC Wainwright & Co.ReiteratesBuy—
27 Dec 2023Ladenburg ThalmannInitiatesBuy—
16 Oct 2023HC Wainwright & Co.MaintainsBuy—
11 Aug 2023HC Wainwright & Co.MaintainsBuy—
17 May 2023HC Wainwright & Co.ReiteratesBuy—
11 May 2023OppenheimerReiteratesOutperform—
20 Mar 2023HC Wainwright & Co.MaintainsBuy—
2 Mar 2023OppenheimerMaintainsOutperform—
17 Nov 2022HC Wainwright & Co.MaintainsBuy—
9 June 2022OppenheimerMaintainsOutperform—
24 May 2022Goldman SachsMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PMVP.

Market Radar

This page is one stock. Monday covers all of them.

PMVP appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PMVP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, PMV Pharmaceuticals, Inc. returned −3.7% against +9.2% for the S&P 500, dividends included.

PMVP vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130Jan 26Apr 26Jul 26Oct 26PMVPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PMVP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
1.7×

Cheaper than 51% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−99.4%

Higher than 13% of US stocks

Return on assets
−39.3%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • PMV Pharmaceuticals, Inc. has a market value of $92.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$75.2M.

  • Free cash flow in the twelve months to 30 June 2026: −$71.3M.

  • Shares outstanding: 53.5M.

  • PMV Pharmaceuticals, Inc. employs 54 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Nov 2026

Data provided by Twelve Data

Peers

PMVP and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PMVPPMV Pharmaceuticals, Inc.$92.2M59
ZURAZura Bio Ltd.$91.6M15
ANIXAnixa Biosciences, Inc.$90.9M61
EQEquillium, Inc.$90.6M52
HURATuHURA Biosciences, Inc.$90.1M24
VANIVivani Medical, Inc.$94.7M44
RANIRani Therapeutics Holdings, Inc.$88.4M63

Take a look at PMVP’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own PMV Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about PMVP

What is the PMVP stock price forecast for 2026-2027?

The median 12-month analyst price target for PMV Pharmaceuticals, Inc. is $4, with estimates ranging from $3 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PMVP stock a buy right now?

Of the 5 analysts covering PMV Pharmaceuticals, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PMV Pharmaceuticals, Inc. 59 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PMVP?

As at 18 Nov 2026, PMV Pharmaceuticals, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (86 of 100).

Will PMVP stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts is $4, and Ticker Nerd's factor model ranks PMV Pharmaceuticals, Inc. 59 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PMVP stock forecast for 2030?

No analyst covering PMV Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PMVP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $5 over the next 12 months.

How has PMVP stock performed over the past year?

PMV Pharmaceuticals, Inc. returned -3.7% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does PMV Pharmaceuticals, Inc. do?

PMV Pharmaceuticals, Inc. is a precision oncology biotechnology company focused on discovering and developing small-molecule therapies that target p53 mutations in cancer. The company’s lead program, rezatapopt, is designed as a selective p53 reactivator for tumors carrying the Y220C mutation, with a tumor-agnostic approach that aims to address cancers across multiple tissue types.

Company

About PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc. is a precision oncology biotechnology company focused on discovering and developing small-molecule therapies that target p53 mutations in cancer. The company’s lead program, rezatapopt, is designed as a selective p53 reactivator for tumors carrying the Y220C mutation, with a tumor-agnostic approach that aims to address cancers across multiple tissue types. PMV Pharmaceuticals concentrates on translational research and clinical development for advanced solid tumors, combining drug discovery with mutation-specific biology to create targeted treatment options. Based in Princeton, New Jersey, the company operates within the broader cancer therapeutics market and is recognized for its work in mutant p53 biology and small-molecule precision medicine.

CEO Dr. David H. Mack Ph.D. · 54 employees · United States · https://www.pmvpharma.com